Full Text View
Tabular View
No Study Results Posted
Related Studies
48-wk Open Label Phase IIIb to Evaluate Efficacy and Safety
This study has been completed.
Study NCT00654602   Information provided by AstraZeneca

First Received on April 3, 2008.   Last Updated on May 27, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Dyslipidaemia
Additional conditions recognized in this trial
Dyslipidemias
Hyperlipoproteinemia Type II
More general conditions related to this trial
Genetic Diseases, Inborn
Hyperlipidemias
Hyperlipoproteinemias
Lipid Metabolism Disorders
Lipid Metabolism, Inborn Errors
Metabolic Diseases
Metabolism, Inborn Errors
Interventions listed in this trial
Rosuvastatin
Maintenance of specific diet
Additional drug interventions recognized in this trial
Lipid Regulating Agents
More general drug interventions related to this trial
Anticholesteremic Agents
Antimetabolites
Enzyme Inhibitors
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
AstraZeneca


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services